Text Size

Effect of Pterygium Excision on Intraocular Lens Power Calculation for Subsequent Cataract Operation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
NCT00563667
First received: November 21, 2007
Last updated: July 6, 2010
Last verified: July 2010
History of Changes
  Purpose

Pterygium is known to induce with-the-rule astigmatism. Excision of pterygium will steepen the cornea and reduce corneal astigmatism. We postulate that the alteration of keratometry reading will indirectly affect the IOL power calculation in cases with concurrent pterygium and cataract. Concurrent pterygium and cataract is common in Hong Kong and other tropical regions. The effect of pterygium excision on intraocular lens power calculation is investigated.


Condition Intervention
Pterygium
Cataract
Astigmatism
 Procedure: pterygium excision

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Pterygium Excision on IOL Power Calculation: Concurrent Cataract and Pterygium

Resource links provided by NLM:

MedlinePlus related topics: Cataract
U.S. FDA Resources

Further study details as provided by Hospital Authority, Hong Kong:

Primary Outcome Measures:
  • IOL power [ Time Frame: 1 and 3 months post pterygium excision ]
  • Astigmatism [ Time Frame: 1 and 3 months post pterygium excision ]

Estimated Enrollment: 40
Study Start Date: December 2003
Estimated Study Completion Date: December 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • All cases with concomitant cataract and primary pterygium, which are indicated for surgery.

Exclusion Criteria:

  • Pterygium smaller than 1mm, which is not visually significant.
  • Double headed pterygium
  • Pterygium obscuring visual axis that preclude keratometry or autorefraction measurements.
  • Previous corneal refractive surgery that alter the keratometric power of the cornea.
  • Patients with medical problems that preclude staged ocular surgery, e.g. dementia, heart disease, on warfarin.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00563667

Locations
China
Prince of Wales Hospital
Hong Kong, China
Alice Ho Miu Ling Nethersole Hospital
Hong Kong, China
Hong Kong Eye Hospital
Hong Kong, China
Sponsors and Collaborators
Hospital Authority, Hong Kong
Investigators
Principal Investigator: Lulu Cheng, Dr Department of DOVS, Prince of Wales Hospital/ The Chinese University of Hong Kong
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00563667     History of Changes
Other Study ID Numbers: CRE-2003.353, HARECCTR0500013
Study First Received: November 21, 2007
Last Updated: July 6, 2010
Health Authority: Hong Kong: Ethics Committee

Keywords provided by Hospital Authority, Hong Kong:
Pterygium
Cataract
Astigmatism

Additional relevant MeSH terms:
Astigmatism
Pterygium
Cataract
Refractive Errors
 Eye Diseases
Conjunctival Diseases
Lens Diseases

ClinicalTrials.gov processed this record on May 23, 2013